Subsequently, this intravenous IL-31 canine pruritus model was used to determine the onset and duration of action of the current commonly used treatments for canine AD such as oclacitinib (Apoquel, Zoetis; Kalamazoo, MI, USA), lokivetmab (Cytopoint, Zoetis) and glucocorticoids [15,16,17]. The gene discussed is IL31; the disease is Pruritus.